• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Gilead Plan Kept Up Hepatitis C Drug Prices, Senators Say

Quote












No wonder GILD is stuck at $105. In June it was $122, the street knew something. You'll hear a lot more about this Not good for Gilead,but good for Abbvie Good for taxpayers and better for veterans.
 




Will be Interesting to watch reaction of investors and the street tomorrow and in the next month. Not good for Gilead at all. Not good for ANY HCV rep in ANY company.
 




anonymous said:
this is serious, if anything, Abbvie comes out a winner here. Price gouging the government and public, While Abbvie sells almost exact same product for much less ? this will hurt Gilead it's already reflected in diving GILD stock which was $122 in June Now it's $105 and dropping
Click to expand...

No it won't hurt GILD, but it doesn't kill patients like your drug.
 








ABBV was up today 88¢ and Holding steady ...GILD has a major problem now ....bigger than you realize Follow the money trail Investors will trickle out driving GILD stock to new lows.
 








last time I looked America was a free market country.
We live in a capitalist country and the price of everything is based on what the market can bare. There senators must be low life Democracts.
They should resign and go live in France.
 




Who are we kidding, drug companies are not about saving lives or providing cost effective treatments. It's about $$$...profits over purpose and if you think anything else, you are only fooling yourself.
 




Street already reflecting congressional investigation
Gilead Sciences, Inc.
NASDAQ: GILD - Dec 2
104.82. DOWN $1.02 (0.96%)

Lucky Abbvie isn't the poster child for gouging
AbbVie Inc
NYSE: ABBV - Dec 2
59.10 UP. 0.09 (0.15%)
 




Find it very interesting that in the press regarding the supposed rip-off prices of Gilead, not one little peep is made regarding the alternative of using cheaper v-pak.

V-pak is not even considered a viable alternative. Not a good sign for HCV franchise.

Glad I dumped ALL my ABBV stock back in mid-$60 price range. If Amgen moves up the biosimiliar of Humira, ABBV stock will really take a major drop.
 












anonymous said:
Find it very interesting that in the press regarding the supposed rip-off prices of Gilead, not one little peep is made regarding the alternative of using cheaper v-pak.

V-pak is not even considered a viable alternative. Not a good sign for HCV franchise.

Glad I dumped ALL my ABBV stock back in mid-$60 price range. If Amgen moves up the biosimiliar of Humira, ABBV stock will really take a major drop.
Click to expand...

Right on the nail. Soo true. Yeah, Vpak is pulling in some bucks but sooo far below espoused company expectations to investors and such a pathetically tiny market share for a drug that is over a year post launch. Not good vibes from HCV. I am personally glad to be in Metabolics instead.
 




anonymous said:
QD Vpak was filed!! Why didn't we launch with QD? BID in 2015? Who was the moron that said it was commercially viable? I want answers!!
Click to expand...

Yes, VP QD has been filed, BUT it is still at a disadvantage because it's three pills taken once a day and there's still ritonivir in the PI and it may still have to be taken with ribavirin AND it's NOT pan genotypic - still only for Geno 1. Please tell me this isn't our next generation! Both Merck and harvoni will have 1 pill QD with no ritonivir and Merck most likely no ribavirin.
Both pan genotypic. This can't be our next generation because if it is... Here we go again WAY behind the 8 ball. Why even bother!!!
 




anonymous said:
Yes, VP QD has been filed, BUT it is still at a disadvantage because it's three pills taken once a day and there's still ritonivir in the PI and it may still have to be taken with ribavirin AND it's NOT pan genotypic - still only for Geno 1. Please tell me this isn't our next generation! Both Merck and harvoni will have 1 pill QD with no ritonivir and Merck most likely no ribavirin.
Both pan genotypic. This can't be our next generation because if it is... Here we go again WAY behind the 8 ball. Why even bother!!!
Click to expand...

Nope. Not the next gen - everything stays the same with original VPak - just once daily dosing. Should come out in the summer 2016.
 




anonymous said:
Nope. Not the next gen - everything stays the same with original VPak - just once daily dosing. Should come out in the summer 2016.
Click to expand...

ABBV charges a WAC price of $84K for a crappy alternative. That's a rip off. When providers say that they have almost 100% success with Harvoni it's hard to argue the value of that drug. Cost of a cure after discounts and rebates is probably 35-45% off of WAC is a cheap compared to older regions and a life with HCV. And don't kid yourselves that the next gen will be able to compete against a pan GT drug.
 




anonymous said:
Yes, VP QD has been filed, BUT it is still at a disadvantage because it's three pills taken once a day and there's still ritonivir in the PI and it may still have to be taken with ribavirin AND it's NOT pan genotypic - still only for Geno 1. Please tell me this isn't our next generation! Both Merck and harvoni will have 1 pill QD with no ritonivir and Merck most likely no ribavirin.
Both pan genotypic. This can't be our next generation because if it is... Here we go again WAY behind the 8 ball. Why even bother!!!
Click to expand...
We are screwed!
 




Top Bottom
Back
Quote